AegirBio AB is implementing a preferential rights issue of units to existing shareholders. Aegirbio is a Swedish diagnostics company offering tests to monitor and optimise the dosing of biological drugs.

AegirBio AB is implementing a preferential rights issue of units to existing shareholders. If the rights issue is fully subscribed for, the company will initially raise approximately SEK 50.5 million before deduction of costs related to the rights issue. If, within the scope of the offer, full subscription occurs and all warrants that are issued in the rights issue are exercised, the company may raise an additional SEK 50.5 million before the deduction of costs related to the rights issue.

Aegirbio is a Swedish diagnostics company offering tests to monitor and optimise the dosing of biological drugs by means of a unique, patented technology platform. AegirBio’s share is listed on Nasdaq First North Growth Market. Moll Wendén acted as legal adviser, Eminova Partners AB acted as financial adviser, and Eminova Fondkommission AB acted as issue agency to AegirBio in connection with the preferential rights issue.

For further information, please see AegirBio’s press release here (only in Swedish).

Moll Wendén’s team has mainly consisted of Henric Stråth (responsible partner), Alexandra Johansson, John Lundberg and Alexander Blom Vigsø.